{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:22:30Z","timestamp":1770988950241,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.critrevonc.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T19:47:48Z","timestamp":1564602468000},"page":"102-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials"],"prefix":"10.1016","volume":"143","author":[{"given":"Leo","family":"Sekine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia Klarmann","family":"Ziegelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Manica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina da Fonte","family":"Pithan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monalisa","family":"Sosnoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius Daudt","family":"Morais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico Soares","family":"Falcetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Rangel","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Antonini","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.07.001_bib0005","first-page":"85","article-title":"Assessing the benefit of continuous treatment in the first trial (MM-020): impact of response in patients with transplant-ineligible newly diagnosed multiple myeloma","volume":"100","author":"Bahlis","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0010","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/j.clml.2015.07.196","article-title":"Impact of response in patients (pts) with stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) treated with continuous lenalidomide + low-dose dexamethasone (Rd) in the first trial","volume":"15","author":"Bahlis","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154870","article-title":"Review of the reporting of survival analyses within randomised controlled trials and the implications for meta-analysis","volume":"11","author":"Batson","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0025","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis","volume":"104","author":"Blommestein","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0030","doi-asserted-by":"crossref","DOI":"10.2174\/1568009617666170330154756","article-title":"Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment","author":"Botta","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0035","doi-asserted-by":"crossref","first-page":"A710","DOI":"10.1016\/j.jval.2016.09.2086","article-title":"Comparative effectiveness of treatment strategies for multiple myeloma in elderly patients: a network meta-analysis","volume":"19","author":"Buchberger","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0040","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2004.02.150","article-title":"The ethics of early stopping rules: who is protecting whom?","volume":"22","author":"Cannistra","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jval.2010.09.001","article-title":"How valuable are multiple treatment comparison methods in evidence-based health-care evaluation?","volume":"14","author":"Cooper","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0060","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0065","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0070","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.clml.2015.07.339","article-title":"Continuous lenalidomide and low-dose dexamethasone for the treatment of patients with newly diagnosed multiple myeloma and renal impairment in the first trial","volume":"15","author":"Dimopoulos","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011054","article-title":"Indirect comparisons: a review of reporting and methodological quality","volume":"5","author":"Donegan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0080","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","author":"Durie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0085","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0090","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2.2","article-title":"Initial phase 3 results of the first (frontline investigation of lenalidomide+dexamethasone versus standard thalidomide) trial (mm-020\/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (PTS) ineligible for stem cell transplantation (SCT)","volume":"122","author":"Facon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0100","first-page":"220","article-title":"Lenalidomide+low-dose dexamethasone (RD) VS. Melphalan-prednisone-thalidomide (MPT) in newly diagnosed multiple myeloma (NDMM) patients (PTS): The first trial","volume":"99","author":"Facon","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0105","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/j.clml.2015.07.330","article-title":"Updated Overall Survival (OS) analysis of the FIRST study: lenalidomide plus low-dose dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM)","volume":"15","author":"Facon","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0110","first-page":"3","article-title":"Updated overall survival analysis of the first study: continuous lenalidomide plus low-dose dexamethasone vs melphalan, prednisone, and thalidomide in patients with newly diagnosed multiple myeloma","volume":"100","author":"Facon","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0115","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8524","article-title":"FIRST study: updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)","volume":"33","author":"Facon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/bmj.38446.498542.8F","article-title":"Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey","volume":"330","author":"Haynes","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0125","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1990.tb02564.x","article-title":"Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden","volume":"74","author":"Hjorth","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0140","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","author":"Hulin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2015.07.324","article-title":"Continuous treatment with lenalidomide and low-dose dexamethasone for patients with transplant-ineligible newly diagnosed multiple myeloma in the first trial: impact of age","volume":"15","author":"Hulin","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0155","first-page":"152","article-title":"Effect of age on efficacy and safety outcomes in patients with newly diagnosed multiple myeloma receiving lenalidomide and low-dose dexamethasone (RD): the first trial","volume":"100","author":"Hulin","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00277-015-2537-2","article-title":"Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible","volume":"95","author":"Hungria","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0165","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/OTT.S123680","article-title":"Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials","volume":"10","author":"Liu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0180","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0185","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1182\/blood.V126.23.4240.4240","article-title":"Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the first trial","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: a European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2141.2005.05779.x","article-title":"Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma","volume":"131","author":"Ludwig","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0200","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0205","first-page":"50","article-title":"Lenalidomide plus dexamethsone (RD) vs melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) in elderly comunity-based newly diagnosed multiple myeloma patients: efficacy and safety results from a phase 3 trial","volume":"98","author":"Magarotto","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0210","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3859.3859","article-title":"Bortezomib plus melphalan-prednisone continues to demonstrate a survival benefit vs melphalan-prednisone in the phase III vista trial in previously untreated multiple myeloma after 3 years\u2019 follow-up and extensive subsequent therapy use","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0220","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0225","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, Melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0230","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0235","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0240","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1002\/sim.6321","article-title":"A selection model for accounting for publication bias in a full network meta-analysis","volume":"33","author":"Mavridis","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0245","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0250","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0255","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0260","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1966.1966","volume":"122","author":"Niesvizky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0265","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0270","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W","article-title":"Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479","volume":"79","author":"Oken","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0275","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0280","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0285","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0290","first-page":"190","article-title":"Bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients: a prospective, randomized, phase III study","volume":"94","author":"Palumbo","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0295","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0300","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0305","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0310","article-title":"A randomized phase 3 trial of melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) vs lenalidomide plus dexamethsone (Rd) in elderly newly diagnosed multiple myeloma patients","volume":"122","author":"Palumbo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0315","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0320","first-page":"15","article-title":"Continuous treatment with lenalidomide improves outcomes in newly diagnosed myeloma patients not eligible for autologous stem cell transplant: results of the myeloma XI trial","volume":"181","author":"Pawlyn","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0325","article-title":"Continuous treatment with lenalidomide improves outcomes in newly diagnosed myeloma patients not eligible for autologous stem cell transplant: results of the myeloma xi trial","volume":"130","author":"Pawlyn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0335","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0345","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0350","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2011.584006","article-title":"A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant","volume":"52","author":"Sacchi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0360","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0365","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0370","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1182\/blood.V126.23.3030.3030","article-title":"Bayesian network meta-analysis (NMA): safety of bortezomib, thalidomide or lenalidomide containing regimens for transplant ineligible multiple myeloma (MM) patients","volume":"126","author":"Satta","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0375","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0380","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0385","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2217\/imt.11.104","article-title":"An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation","volume":"3","author":"Spicka","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0390","first-page":"220","article-title":"E1A06: a phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma MM)","volume":"99","author":"Stewart","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0395","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0400","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1532\/IJH97.03115","article-title":"Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP\/MP) versus modified COP\/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301","volume":"79","author":"Takenaka","year":"2004","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0410","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10147-015-0826-3","article-title":"Current therapeutic strategies for multiple myeloma","volume":"20","author":"Torimoto","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0415","first-page":"1","article-title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","author":"Weisel","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0420","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0425","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1197\/jamia.M2297","article-title":"Improving efficacy of PubMed clinical queries for retrieving scientifically strong studies on treatment","volume":"14","author":"Wilczynski","year":"2007","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0430","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3163\/1536-5050.95.2.117","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"95","author":"Wilczynski","year":"2007","journal-title":"J. Med. Libr. Assoc."},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0435","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.179.179","volume":"124","author":"Zweegman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.07.001_bib0440","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818304955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818304955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:30:54Z","timestamp":1760902254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818304955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":88,"alternative-id":["S1040842818304955"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}